|Chemical and physical data|
|Molar mass||145.5 g/mol g·mol−1|
Bermekimab (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A). As of March 2017[update], bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.
Bermekimab is being developed by XBiotech Inc.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Bermekimab, American Medical Association.
- Hong, David S; Hui, David; Bruera, Eduardo; Janku, Filip; Naing, Aung; Falchook, Gerald S; Piha-Paul, Sarina; Wheler, Jennifer J; Fu, Siqing; Tsimberidou, Apostolia M; Stecher, Michael; Mohanty, Prasant; Simard, John; Kurzrock, Razelle (May 2014). "MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study". The Lancet Oncology. 15 (6): 656-66. doi:10.1016/S1470-2045(14)70155-X. Retrieved 3 March 2017.
- "A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 3 March 2017.
- "A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 18 December 2018.
- "Xilonix™ True Human™ monoclonal antibody by Xbiotech oncology". www.xbiotech.com. XBiotech. Retrieved 3 March 2017.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|